Ryvu Therapeutics (LTS:0RKT) Cyclically Adjusted Revenue per Share: zł4.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKT Ryvu Therapeutics SA LTS:0RKT
66 GF Score
Price zł30.25
GF Value zł93.11
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Cyclically Adjusted Revenue per Share?

Ryvu Therapeutics LTS:0RKT 66 Cyclically Adjusted Revenue per Share is zł4.63 as of Mar. 2026. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł93.11. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ryvu Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was zł0.733. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł4.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ryvu Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -4.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ryvu Therapeutics was 9.50% per year. The lowest was 1.60% per year. And the median was 5.55% per year.

As of today (2026-07-23), Ryvu Therapeutics's current stock price is zł30.25. Ryvu Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was zł4.63. Ryvu Therapeutics's Cyclically Adjusted PS Ratio of today is 6.53.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ryvu Therapeutics was 23.68. The lowest was 4.00. And the median was 14.58.


Ryvu Therapeutics  (LTS:0RKT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ryvu Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=30.25/4.63
=6.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ryvu Therapeutics was 23.68. The lowest was 4.00. And the median was 14.58.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ryvu Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Ryvu Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Cyclically Adjusted Revenue per Share Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.39 3.83

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.71 3.35 3.83 3.83 4.63

LTS:0RKT vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ryvu Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Cyclically Adjusted PS Ratio falls into.


LTS:0RKT
66GF Score
Ryvu Therapeutics SA LTS:0RKT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ryvu Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.733/163.0700*163.0700
=0.733

Current CPI (Mar. 2026) = 163.0700.

Ryvu Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.808 99.552 1.324
201609 0.851 99.064 1.401
201612 1.358 100.366 2.206
201703 1.778 101.018 2.870
201706 2.011 101.180 3.241
201709 1.232 101.343 1.982
201712 1.256 102.564 1.997
201803 1.119 102.564 1.779
201806 1.213 103.378 1.913
201809 -1.829 103.378 -2.885
201812 2.733 103.785 4.294
201903 0.067 104.274 0.105
201906 0.054 105.983 0.083
201909 0.076 105.983 0.117
201912 0.041 107.123 0.062
202003 0.487 109.076 0.728
202006 0.434 109.402 0.647
202009 0.027 109.320 0.040
202012 0.014 109.565 0.021
202103 0.015 112.658 0.022
202106 0.017 113.960 0.024
202109 0.007 115.588 0.010
202112 0.534 119.088 0.731
202203 0.002 125.031 0.003
202206 0.002 131.705 0.002
202209 0.725 135.531 0.872
202212 1.341 139.113 1.572
202303 0.579 145.950 0.647
202306 0.453 147.009 0.502
202309 0.528 146.113 0.589
202312 0.484 147.741 0.534
202403 0.935 149.044 1.023
202406 0.725 150.997 0.783
202409 0.624 153.439 0.663
202412 1.105 154.660 1.165
202503 0.732 157.021 0.760
202506 0.553 157.509 0.573
202509 0.664 158.000 0.685
202512 0.779 158.320 0.802
202603 0.733 163.070 0.733

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł4.63 mean?
Ryvu Therapeutics (LTS:0RKT) has a Cyclically Adjusted Revenue per Share of zł4.63 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' Cyclically Adjusted Revenue per Share too high?
Ryvu Therapeutics' current Cyclically Adjusted Revenue per Share is zł4.63. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Ryvu Therapeutics' Cyclically Adjusted Revenue per Share of zł4.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current Cyclically Adjusted Revenue per Share is zł4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Cyclically Adjusted Revenue per Share of zł4.63. The stock's GF Value™ is zł93.11, compared to a current price of zł30.25 — trading 67.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł4.63. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Cyclically Adjusted Revenue per Share is zł4.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł30.25 is trading 67.5% below its estimated GF Value™ of zł93.11.

Key valuation signals for LTS:0RKT:

  • Cyclically Adjusted Revenue per Share: zł4.63
  • GF Value™: zł93.11 vs. price of zł30.25 (67.5% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for LTS:0RKT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.25
Price
zł93.11
GF Value